Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
J Surg Oncol
; 128(3): 478-488, 2023 Sep.
Article
in En
| MEDLINE
| ID: mdl-37537982
ABSTRACT
Tenosynovial giant cell tumor (TGCT) is a rare, benign, locally aggressive synovial based neoplastic process that can result in functional debilitation and end-stage arthrtitis. Although surgical resection is the primary treatment modality, novel systemic therapies are emerging as part of the multimodal armamentarium for patients with unresectable or complex disease burden. This review discusses the pathogenesis of TGCT, potential druggable targets and therapeutic approaches. It also evaluates the safety and efficacy of different systemic therapies.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Giant Cell Tumor of Tendon Sheath
/
Giant Cell Tumors
Limits:
Humans
Language:
En
Journal:
J Surg Oncol
Year:
2023
Document type:
Article
Affiliation country: